Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
11 hedge funds and large institutions have $114K invested in Aoxing Pharmaceutical Company Inc. in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.06% less ownership
Funds ownership: 0.29% → 0.23% (-0.06%)
46% less capital inflows, than outflows
Capital inflows: $37.2K | Capital outflows: $69.3K
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$16.9K |
| 2 |
Focused Wealth Management
Newburgh,
New York
|
+$14.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.81K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$98 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Fund Advisors
San Francisco,
California
|
-$47.2K |
| 2 |
Virtu KCG Holdings
New York
|
-$11K |
| 3 |
BlackRock Investment Management
Wilmington,
Delaware
|
-$5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.35K |
| 5 |
MUFG Americas
New York
|
-$2K |
AXN Hedge Fund Activity: Q2 2016 in Review
11 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q2 2016, worth a combined $114K — down 22% from $147K a quarter earlier.
Fund positioning in AXN was balanced in Q2 2016: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $16.9K. The largest seller was BlackRock Fund Advisors, cutting an estimated $47.2K.
- 11 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $114K of Aoxing Pharmaceutical Company Inc. stock for Q2 2016, down 22% quarter-over-quarter.
- 3 funds opened new Aoxing Pharmaceutical Company Inc. positions in Q2 2016 and 3 closed out, a net change of 0 holders.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q2 2016 was Barclays, an estimated $16.9K added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q2 2016 was BlackRock Fund Advisors, an estimated $47.2K sold.
Based on aggregated 13F filings for Q2 2016.